Zobrazeno 1 - 10
of 252
pro vyhledávání: '"Bukatina, A."'
Autor:
T. M. Bukatina, E. V. Shubnikova
Publikováno v:
Безопасность и риск фармакотерапии, Vol 12, Iss 2, Pp 201-213 (2024)
INTRODUCTION. A risk management plan (RMP) is an important document for assessing and managing risks when using a medicinal product. An RMP is provided as part of the marketing authorisation application for a medicinal product. The requirements for t
Externí odkaz:
https://doaj.org/article/02c1e5f5d6ee40a99d9ef960cf955453
Publikováno v:
Безопасность и риск фармакотерапии, Vol 11, Iss 3, Pp 292-302 (2023)
Scientific relevance. Lowering low-density lipoprotein cholesterol (LDL-C) levels with statins is a generally accepted standard treatment for dyslipidaemia. However, adverse reactions and intolerance to statins have motivated the search for lipid-mod
Externí odkaz:
https://doaj.org/article/d668b2b1200f4b0ab2b0e411b0a7343d
Autor:
Margarita Bukatina
Publikováno v:
Вестник Волгоградского государственного университета. Серия 4. История, регионоведение, международные отношения, Iss 1, Pp 65-76 (2023)
Introduction. The invasion of the Soviet Union by Nazi troops and the Battle of Stalingrad greatly affected all aspects of life in the Lower Volga Region. Ensuring the economy of the whole country and resistance to the invader was carried out by the
Externí odkaz:
https://doaj.org/article/166e367361c943b182a44747c94fe912
Autor:
T. M. Bukatina, E. V. Shubnikova
Publikováno v:
Безопасность и риск фармакотерапии, Vol 11, Iss 1, Pp 30-37 (2023)
The Council of the Eurasian Economic Commission published Decision No. 81 “On Amendments to the Rules of Good Pharmacovigilance Practice of the Eurasian Economic Union” on 19 June 2022 and enacted it on 6 December 2022. A risk management plan (RM
Externí odkaz:
https://doaj.org/article/d4c7ef2297034442b9c3ec0d9c4a8568
Autor:
E. V. Shubnikova, T. M. Bukatina, A. A. Druzhinina, E. O. Zhuravleva, G. V. Kutekhova, N. Yu. Velts
Publikováno v:
Безопасность и риск фармакотерапии, Vol 10, Iss 2, Pp 196-199 (2022)
The experts of the Scientific Centre for Expert Evaluation of Medicinal Products analysed administrative decisions of foreign regulatory authorities on the recalls of antibacterial and antiprotozoal medicinal products and/or the need for labelling up
Externí odkaz:
https://doaj.org/article/a63e51bcbf574109bf86f81a4ec4b204
Publikováno v:
Безопасность и риск фармакотерапии, Vol 10, Iss 1, Pp 19-33 (2022)
The search for an effective and safe COVID-19 therapy involves, among other things, assessment of efficacy of medicines already used for the treatment of other diseases, and having potential antiviral activity against SARS-CoV-2. The relevance of the
Externí odkaz:
https://doaj.org/article/1b15e6f738d9463bab69713906de8cff
Autor:
T. M. Bukatina, E. V. Shubnikova
Publikováno v:
Безопасность и риск фармакотерапии, Vol 10, Iss 1, Pp 6-12 (2022)
The pharmacovigilance system plays one of the key roles in ensuring safety and efficacy of medicine use. The risk management process helps to ensure the most favourable benefit/risk ratio of a medicine or combination of medicines both for the target
Externí odkaz:
https://doaj.org/article/abb2da6596e746f98085ec13e6defd61
Publikováno v:
Безопасность и риск фармакотерапии, Vol 8, Iss 3, Pp 134-140 (2020)
In 1968 the World Health Organisation initiated the development of an international programme for collection of data from the maximum number of sources about potential adverse effects of medicines. In order to implement this programme, a number of da
Externí odkaz:
https://doaj.org/article/731a6e464b414fb6a6a234a208c9a209
Publikováno v:
Безопасность и риск фармакотерапии, Vol 8, Iss 1, Pp 9-22 (2020)
The introduction into clinical practice of immune checkpoint inhibitors that block cytotoxic T-lymphocyte-associated protein 4 (CTLA-4), programmed cell death protein-1 (PD-1), and programmed cell death ligand-1 (PD-L1), has improved the prognosis of
Externí odkaz:
https://doaj.org/article/11e329a083234c8a9f618ff122d1c4d5
Publikováno v:
Безопасность и риск фармакотерапии, Vol 8, Iss 4, Pp 211-213 (2020)
Experts of the Department for Evaluation of Medicinal Products’ Safety of the Scientific Centre for Expert Evaluation of Medicinal Products analysed administrative decisions of foreign regulatory authorities on limiting the use of some medicinal pr
Externí odkaz:
https://doaj.org/article/de0442d8cae3492cbb42cdb933866786